Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein sold 13,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.75, for a total value of $1,023,750.00. Following the completion of the sale, the chief executive officer now owns 13,000 shares of the company’s stock, valued at approximately $1,023,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Agios Pharmaceuticals Inc (AGIO) traded down $1.97 during trading hours on Monday, reaching $73.87. The company’s stock had a trading volume of 558,171 shares, compared to its average volume of 919,628. Agios Pharmaceuticals Inc has a 1 year low of $43.32 and a 1 year high of $82.96. The firm has a market capitalization of $3,700.00, a PE ratio of -11.78 and a beta of 2.12.
Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 762 shares during the period. QS Investors LLC acquired a new position in Agios Pharmaceuticals in the second quarter valued at about $144,000. State of Alaska Department of Revenue acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at about $160,000. Teacher Retirement System of Texas acquired a new position in Agios Pharmaceuticals in the third quarter valued at about $225,000. Finally, S&CO Inc. acquired a new position in Agios Pharmaceuticals in the third quarter valued at about $227,000. 82.67% of the stock is owned by hedge funds and other institutional investors.
A number of research firms recently commented on AGIO. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price objective for the company in a report on Tuesday, January 16th. Oppenheimer reiterated a “buy” rating and issued a $83.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, December 11th. Finally, Royal Bank of Canada upped their price objective on Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a report on Thursday, January 18th. They noted that the move was a valuation call. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $77.64.
ILLEGAL ACTIVITY WARNING: This news story was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thestockobserver.com/2018/02/05/agios-pharmaceuticals-inc-agio-ceo-sells-1023750-00-in-stock.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.